GlassScriptPhysician profile
Christopher William Rice
NPI 1235584335
$6,579.50
in general payments reported to CMS, 2019-2025
24 companies · $1,591 in 2025
The $1,591 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.66 · 2020: $13.75 · 2021: $303 · 2022: $1,804 · 2023: $1,379 · 2024: $1,477 · 2025: $1,591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,368 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,367.73 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,785.76 | 2021-2025 | Enbrel, Otezla, Otezla |
| Abbvie INC. | $1,638.73 | 2021-2025 | |
| Janssen Biotech, INC. | $926.82 | 2021-2025 | Tremfya |
| Ucb, INC. | $346.29 | 2022-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $313.21 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $289.49 | 2021-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $245.13 | 2022-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $198.91 | 2022-2025 | |
| Glaxosmithkline, LLC. | $143.90 | 2021-2025 | Benlysta, Nucala |
| Lilly USA, LLC | $130.57 | 2021-2025 | Taltz |
| Genzyme Corporation | $90.22 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.04 | 2022-2024 | Ofev, Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $78.17 | 2024-2025 | Orencia |
| Aurinia Pharma U.S., INC. | $71.08 | 2022-2023 | Lupkynis |
| Fresenius Kabi USA, LLC | $57.57 | 2024-2025 | Idacio |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $33.76 | 2021-2022 | |
| Almatica Pharma LLC | $21.65 | 2024 | Teriparatide |
| Genentech USA, INC. | $20.94 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.43 | 2025 | Strensiq |
| Sandoz INC. | $19.77 | 2023 | Hyrimoz |
| Radius Health, INC. | $19.37 | 2024 | Tymlos |
| Horizon Therapeutics Plc | $18.67 | 2023 | Krystexxa |
| Ferring Pharmaceuticals INC. | $13.27 | 2021 | |
| Ani Pharmaceuticals, INC. | $11.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Rice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.